- Business Wire•2 hours ago
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the underwriters for its public offering of 3,750,000 shares of its common stock at $40.00 per share have elected to exercise in full their option to purchase up to an additional 562,500 shares of common stock at the public offering price, less the underwriting discounts and commissions.
Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma's stock price. Get the deal done, even if you have to sell it to the shorts.
- Insider Monkey•yesterdayUps And Downs In Biotech This Week: PTC Therapeutics, Inc. (PTCT), Puma Biotechnology Inc (PBYI) and Nektar Therapeutics (NKTR)
It’s been another busy start to the week in biotech, with a number of companies moving double digit percentage points on various fundamental releases. Here are a few of the most notable, and a look at what’s moving the markets for each. We’ll kick things off with two capital structure driven moves, focusing on Puma […]
Puma Biotechnology, Inc. (PBYI)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||44.35 x 200|
|Ask||44.50 x 100|
|Day's Range||42.55 - 45.30|
|52wk Range||19.74 - 94.93|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.59|
|Avg Vol (3m)||1,068,555|
|Dividend & Yield||N/A (N/A)|